英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03696 英矽智能

休市中 10-16 16:08:16

39.100

+1.460

+3.88%

最高40.280	最低38.120	成交量1,571万
今开39.160	昨收37.640	日振幅5.74%
总市值228.74亿	流通市值228.74亿	总股本5.85亿
成交额6.19亿	换手率2.69%	流通股本5.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03696","market":"HK","secType":"STK","nameCN":"英矽智能","latestPrice":39.1,"timestamp":1792138096008,"preClose":37.64,"halted":0,"volume":15714586,"delay":0,"changeRate":0.03878852284803403,"floatShares":585000000,"shares":585000000,"eps":-4.48,"marketStatus":"休市中","change":1.46,"latestTime":"10-16 16:08:16","open":39.16,"high":40.28,"low":38.12,"amount":618900826,"amplitude":0.057386,"askPrice":39.1,"askSize":12000,"bidPrice":39.08,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-4.006,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1767024000000,"exchange":"SEHK","adjPreClose":37.64,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.9249359531929465,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03696","defaultTab":"news","newsList":[{"id":"1106793080","title":"异动解读｜英矽智能盘中上涨6.06%，AI制药板块反弹带动股价修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1106793080","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106793080?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114670,"startTime":"0","endTime":"0","summary":"10月16日，英矽智能盘中上涨6.06%，报39.88港元，成交额7702.55万港元。消息面上，近期压制股价的AI制药板块回调出现缓和，同行晶泰控股涨4.67%，药明生物涨3.41%，药明康德涨2.99%，板块修复带动英矽智能反弹。公司此前已提名第35款临床前候选化合物ISM9546，用于炎症性肠病、类风湿性关节炎等自身免疫疾病；该药物由Pharma.AI平台设计。此前该进展未能扭转抛压，如今在板块情绪改善下，股价出现修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AI制药板块回暖，英矽智能股价修复","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105907568","title":"异动解读｜英矽智能盘中下跌5.24%，AI制药板块回调延续叠加新候选药提名未改抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1105907568","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105907568?lang=zh_cn&edition=full","pubTime":"2026-10-15 11:49","pubTimestamp":1792036169,"startTime":"0","endTime":"0","summary":"10月15日，英矽智能盘中下跌5.24%，报39.42港元，成交额3.97亿港元。消息面上，公司日前宣布将ISM9546提名为临床前候选化合物，潜在用于炎症性肠病、类风湿性关节炎等自身免疫疾病；该药物由Pharma.AI平台设计，也是公司自2021年以来第35款临床前候选化合物。但最新管线进展未带来股价正反馈，近期AI制药板块已连续回调，资金高位兑现压力仍在；同时，摩根大通此前减持公司H股、好仓比例降至5.96%，机构持仓变化亦持续扰动市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AI制药续挫，英矽智能新候选药难阻回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194862473","title":"异动解读｜英矽智能盘中下跌5.18%，AI制药板块回调叠加新候选药提名未改资金兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1194862473","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194862473?lang=zh_cn&edition=full","pubTime":"2026-10-14 15:23","pubTimestamp":1791962611,"startTime":"0","endTime":"0","summary":"10月14日，英矽智能盘中下跌5.18%，报41.32港元，成交额3.95亿港元。本次异动对应的公开消息面，主要是公司日前宣布将ISM9546提名为临床前候选化合物，用于炎症性肠病、类风湿性关节炎等自身免疫性疾病；该药物由Pharma.AI平台设计，也是公司自2021年以来第35款临床前候选化合物。不过，最新催化并未带来股价正反馈。此前市场已出现AI制药板块整体承压、资金高位兑现的表述，且摩根大通于10月6日减持公司H股，好仓比例降至5.96%，机构持仓变化亦对情绪形成扰动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AI制药板块回调，英矽智能盘中走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118444626","title":"异动解读｜英矽智能盘中下跌5.37%，AI制药板块集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1118444626","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118444626?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:37","pubTimestamp":1791855439,"startTime":"0","endTime":"0","summary":"10月13日，英矽智能盘中下跌5.37%，报44.68港元，成交额8444.38万港元。AI制药板块整体承压，资金延续前期高位兑现态势，英矽智能随板块联动走弱。此前摩根大通于10月6日减持英矽智能H股，好仓比例由6.13%降至5.96%，机构持仓变动或在一定程度上影响市场情绪。英矽智能主要从事人工智能驱动的药物发现及管线开发业务，通过自主开发的人工智能平台Pharma.AI产生多项临床或新药临床试验申请阶段的资产，并涉足软件解决方案及其他非制药领域研发业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132422508","title":"英矽智能（03696）宣布提名第35款临床前候选化合物ISM9546","url":"https://stock-news.laohu8.com/highlight/detail?id=1132422508","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132422508?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:26","pubTimestamp":1791851191,"startTime":"0","endTime":"0","summary":"2026年10月13日，英矽智能发布自愿公告称，公司已将ISM9546正式提名为临床前候选化合物。在多项细胞实验中，ISM9546表现出纳摩尔级活性，并借助其外周限制性特性，旨在降低与中枢神经系统相关的风险。英矽智能表示，ISM9546的发现与优化得益于公司专有的Pharma.AI解决方案。公告最后，英矽智能建议股东及潜在投资者在买卖公司股份时保持审慎，并在需要时寻求专业意见。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675938509","title":"英硅智能(03696)提名外周限制性 VAV1 分子胶降解剂潜在用于多种自身免疫性疾病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675938509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675938509?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:16","pubTimestamp":1791850604,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能(03696)发布公告，本公司提名ISM9546为临床前候选化合物 (PCC)。其为一款创新、口服、外周限制性VAV1分子胶降解剂，潜在用于多种自身免疫性疾病治疗，包括炎症性肠病(IBD)与类风湿性关节炎(RA)等。在英硅智能专有的Pharma.AI解决方案的赋能下，ISM9546不仅是本公司自2021年以来提名的第35款PCC，更在疗效与安全性之间取得平衡，在多个细胞实验中表现出纳摩尔级活性，并透过其外周限制性特征，潜在降低与中枢神经系统(CNS)相关的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168902807","title":"异动解读｜英矽智能盘中下跌5.7%，AI制药板块集体回调引发获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1168902807","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168902807?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:38","pubTimestamp":1791423536,"startTime":"0","endTime":"0","summary":"10月8日，英矽智能盘中下跌5.7%，报49.98港元，成交额2.98亿港元。消息面上，AI制药板块近期连续上涨后出现集体回调，资金集中兑现前期涨幅。此前一日，英矽智能已下跌10.62%，晶泰控股跌幅达12.1%，板块内多只AI创新药标的同步下挫。市场分析认为，AI制药虽为长期产业趋势，但多数企业仍处于管线验证阶段，商业化兑现周期长，短期估值抬升后面临获利盘了结压力。英矽智能主要从事人工智能驱动的药物发现及管线开发业务，通过自研Pharma.AI平台产生多项临床或新药临床试验申请阶段资产，同时涉足软件解决方案及其他非制药领域研发业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英矽智能盘中下挫，AI制药板块集体回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116443173","title":"英矽智能更新9月股份变动月报表，总股本增至585,120,194股","url":"https://stock-news.laohu8.com/highlight/detail?id=1116443173","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116443173?lang=zh_cn&edition=full","pubTime":"2026-10-07 17:11","pubTimestamp":1791364300,"startTime":"0","endTime":"0","summary":"英矽智能于2026年10月7日发布了截至2026年9月30日的股份变动月报表。公告显示，公司于本月末的注册股本保持1,270,000,000股，面值为每股USD 0.0000005，总注册股本为USD 635，较上月底无变化。根据月报，英矽智能本月已发行股份由582,684,110股增至585,120,194股，新增2,436,084股。截至9月末，英矽智能已满足上市规则要求的公众持股量比例。公告显示，英矽智能坚持遵守香港联合交易所有限公司《上市规则》以及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131777234","title":"异动解读｜英矽智能盘中下跌8.68%，AI制药板块集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1131777234","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131777234?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:33","pubTimestamp":1791336781,"startTime":"0","endTime":"0","summary":"10月7日，英矽智能盘中下跌8.68%，报54.25港元，成交额3728.62万港元。此次提名推动公司在2026年前9个月内累计提名10款PCC，刷新年度管线产出纪录。尽管AI制药领域中长期逻辑仍受市场关注，但板块内个股短期波动加大。英矽智能主要从事人工智能驱动的药物发现及管线开发业务，通过自研Pharma.AI平台产生多项临床或新药临床试验申请阶段资产，同时涉足软件解决方案及其他非制药领域研发业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英矽智能盘中回调，AI制药板块集体走弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673035134","title":"小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035134?lang=zh_cn&edition=full","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995153.HKD","IE00BKDWB100.SGD","IYG","XLBI","LU2168564065.EUR","159760","LU0345769128.USD","GDOC","XLF","02268","LU1670627923.USD","WX","VHT","AGNG","VFH","06990","FNCL","LU0572944931.SGD","LNGR","TFNS","LU0345769631.USD","TRUF","02359","IEIH","HBImain","IBBJ","03696","159837","MEDX","KURE","LU0976567544.SGD","XBI","XLV","02269","UYG","01548","EQRR","CXO","LU1974910355.USD","IXG","IYF","LABU","PEX","KBWB","SYNB","JPO","IXJ","FTXO","IE0034235295.USD","JPMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191392252","title":"异动解读｜英矽智能盘中下跌5.16%，报56.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191392252","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191392252?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:31","pubTimestamp":1790904681,"startTime":"0","endTime":"0","summary":"10月2日，英矽智能盘中下跌5.16%，报56.7港元/股，成交额1160.44万港元。英矽智能所在的生命科学工具和服务行业整体承压，个股中，药明康德跌2.97%，药明生物跌1.07%，金斯瑞生物科技跌1.78%，药明合联跌2.44%，晶泰控股跌2.44%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671278341","title":"英硅智能（03696）涨超7% 自研生成式AI平台推出代谢病候选化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2671278341","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671278341?lang=zh_cn&edition=full","pubTime":"2026-09-30 13:39","pubTimestamp":1790746770,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英硅智能（03696）早盘股价扬升，午后维持高位，最新涨7.67%，报59.65港元，成交额7.44亿港元。消息面上，9月30日，英硅智能宣布，在英硅智能自有生成式AI平台驱动下，公司提名ISM1354（一款潜在“同类最佳”、新一代小分子葡萄糖依赖性促胰岛素多肽受体（GIPR）拮抗剂）作为临床前候选化合物（PCC），潜在用于肥胖及2型糖尿病等相关疾病干预，并有望拓展到心血管疾病领域。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992870","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTHR","AGIX","QTOC","CHAT","03696","BK1141","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671122767","title":"英硅智能(03696)提名新一代小分子 GIPR 拮抗剂，潜在用于肥胖与相关疾病干预","url":"https://stock-news.laohu8.com/highlight/detail?id=2671122767","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671122767?lang=zh_cn&edition=full","pubTime":"2026-09-30 12:24","pubTimestamp":1790742274,"startTime":"0","endTime":"0","summary":"英硅智能公布，在英硅智能自有生成式AI平台驱动下，公司提名ISM1354作为临床前候选化合物，潜在用于肥胖及2型糖尿病等相关疾病干预，并有望拓展到心血管疾病领域。截至目前，英硅智能在2026年前9个月内宣布提名10款PCC，刷新了公司年度管线产出的历史记录，将2021年以来提名的PCC总数推升至34款，从而以可复现的真实世界案例验证生成式AI研发效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GIPR","03696","BK4160","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165240693","title":"英矽智能(03696)提名ISM1354为临床前候选化合物 进一步完善肥胖及代谢疾病治疗管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1165240693","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165240693?lang=zh_cn&edition=full","pubTime":"2026-09-30 12:21","pubTimestamp":1790742060,"startTime":"0","endTime":"0","summary":"2026年9月30日，英矽智能发布自愿公告，宣布在其生成式AI平台支持下，成功提名ISM1354为临床前候选化合物。ISM1354是一款新一代小分子葡萄糖依赖性促胰岛素多肽受体拮抗剂，拟用于肥胖和2型糖尿病等相关疾病干预，并有望拓展至心血管疾病领域。截至目前，英矽智能已在2026年前9个月内累计提名10款临床前候选化合物，刷新了公司年度管线产出纪录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671722150","title":"港股异动 | 英硅智能(03696)涨近8% AI制药赛道持续升温 公司BD及PCC产出创纪录高","url":"https://stock-news.laohu8.com/highlight/detail?id=2671722150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671722150?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:03","pubTimestamp":1790733803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英硅智能涨近8%，截至发稿，涨7.85%，报59.75港元，成交额3.63亿港元。消息面上，截至最新数据，英硅智能在2026年内披露的签约合作总额已达约 73亿美元，累计对外授权交易总值达110亿美元。在AI驱动的研发方面，英硅智能在今年前9个月内提名了9个临床前候选化合物，刷新了公司年度管线产出的历史纪录。花旗指出，英硅智能仍为该行人工智能药物发现子板块首选。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1141","VXUS","KCAI","VTHR","CHAT","AGIX","BK4588","BK4585","BK1574","QTOC","03696","ARTY","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182919490","title":"异动解读｜英矽智能盘中上涨5.96%，数千万美元AI模型共建合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1182919490","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182919490?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:43","pubTimestamp":1790732595,"startTime":"0","endTime":"0","summary":"9月30日，英矽智能盘中上涨5.96%，报58.65港元，成交额2.09亿港元。消息面上，公司近期宣布与一家前沿基础模型实验室达成合约金额最高达数千万美元的AI联合开发合作，双方将依托MMAI Gym训练框架，共同开发、验证并商业化面向生物学研究的基础模型，并建立收益共享模式推动全球商业化。该合作自公布以来持续受到市场关注，此前交易日股价已有所反应。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英矽智能盘中异动上涨，AI模型合作持续催化","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671260807","title":"港股异动 | 英硅智能(03696.HK)早盘涨超4% 近期宣布达成数千万美元AI模型共建合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2671260807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671260807?lang=zh_cn&edition=full","pubTime":"2026-09-29 11:42","pubTimestamp":1790653339,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117953142","title":"英矽智能：Norges Bank减持，好仓比例降至3.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117953142","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117953142?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:16","pubTimestamp":1790241364,"startTime":"0","endTime":"0","summary":"于2026年9月22日，Norges Bank因收回抵押股份（Collateral shares returned），通过场外非现金资产交易减持英矽智能股份。该笔交易属场外交易（代价性质：非现金资产），未经联交所公开市场撮合，不属二级市场直接买卖。Norges Bank此次减持前持有英矽智能好仓3025.12万股，占比5.19%；减持后持股量为1832.71万股，好仓比例降至3.15%。淡仓方面，减持前持有2083.73万股（3.58%），减持后持有891.31万股（1.53%）。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669452145","title":"富瑞：英硅智能(03696.HK)药物资产重要性胜于专有模型 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669452145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669452145?lang=zh_cn&edition=full","pubTime":"2026-09-24 14:48","pubTimestamp":1790232501,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166047228","title":"异动解读｜英矽智能盘中下跌5.03%，增发新股摊薄叠加生命科学板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1166047228","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166047228?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:57","pubTimestamp":1790229458,"startTime":"0","endTime":"0","summary":"9月24日，英矽智能盘中下跌5.03%，报55.7港元/股，成交额6.49亿港元，延续前一交易日跌势。消息面上，公司近期因增发新股，导致董事长Aleksandrs Zavoronkovs持股比例由8.02%被动摊薄至7.99%，市场对股本扩张存在一定担忧。与此同时，生命科学工具和服务板块整体承压，金斯瑞生物科技跌6.18%，晶泰控股跌3.10%，药明生物跌2.18%，药明合联跌1.37%，药明康德跌1.16%，行业个股全线下挫，进一步拖累公司股价表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英矽智能增发摊薄，随板块走弱下探","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://insilico.com","stockEarnings":[{"period":"1week","weight":-0.202},{"period":"1month","weight":-0.2227},{"period":"3month","weight":-0.0949},{"period":"6month","weight":-0.3569},{"period":"1year","weight":0.6258},{"period":"ytd","weight":0.0528}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英矽智能是一家主要从事人工智能驱动的药物发现及管线开发业务的公司。该公司主要业务包括自主开发候选药物，共同开发，授权药物并保留部分知识产权及与其他制药公司合作但不保留任何知识产权。该公司通过自主开发的人工智能平台 Pharma.AI产生了多项临床或新药临床试验申请阶段的资产。此外，该公司也涉足软体解决方案和其他与非制药领域相关的研发业务。","exchange":"SEHK","name":"英矽智能","nameEN":"INSILICO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英矽智能,03696,英矽智能股票,英矽智能股票老虎,英矽智能股票老虎国际,英矽智能行情,英矽智能股票行情,英矽智能股价,英矽智能股市,英矽智能股票价格,英矽智能股票交易,英矽智能股票购买,英矽智能股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英矽智能(03696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英矽智能(03696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}